NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · TWST · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Twist Bioscience Corporation’s quoted price sits in the upper half of its reported 52-week range, 21.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Twist Bioscience Corporation’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.38. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Twist Bioscience Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | May 5, 2025 | -$0.66-17.86% vs estimate | $92.79M-2.72% vs estimate |
|---|
| Q1 2025 | Feb 3, 2025 | -$0.53+14.52% vs estimate | $88.71M+2.03% vs estimate |
|---|
| Q4 2024 | Nov 18, 2024 | -$0.59+17.35% vs estimate | $84.71M+2.41% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 10 contributors · Median target $147.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
CN¥143.50+CN¥0.61 (+0.43%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.34% below the high.
₩1,417,000+₩51,000 (+3.73%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.69% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
HK$44.86-HK$0.20 (-0.44%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
$188.64+$3.95 (+2.14%)
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
HK$36.98-HK$0.72 (-1.91%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 25.23% below the high.
